Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Gastroenterology. 2022 Apr;162(4):1256-1271.e14. doi: 10.1053/j.gastro.2021.12.249. Epub 2021 Dec 21.
BACKGROUND & AIMS: Pancreatic ductal adenocarcinoma (PDAC) is characterized by severe metabolic stress due to fibrosis and poor vascularization. BZW1 is an eIF5-mimic protein involved in tumorigenesis and progression. The aim of this study was to investigate the role of BZW1 in metabolic stress resistance in PDAC.
BZW1 expression was evaluated in human PDAC tissue microarray and PDAC cells. Glycolysis regulation of BZW1 and its correlation with glycolysis-related genes was analyzed. Tumor growth, cell proliferation, and apoptosis were evaluated in mice xenograft tumors and patient-derived organoids.
The results of bioinformatic screening identified that BZW1 was 1 of the top 3 genes favorable for tumor progression in PDAC. The analysis of our cohort confirmed that BZW1 was overexpressed in human PDAC tissues compared with nontumor tissues, and its abnormal expression was correlated with large tumor size and poor prognosis. BZW1 promoted cell proliferation and inhibited apoptosis in both mouse xenograft models and PDAC-derived organoids via facilitating glycolysis in the oxygen-glucose-deprivation condition. Mechanically, BZW1 served as an adaptor for PKR-like endoplasmic reticulum (ER) kinase (PERK), facilitated the phosphorylation of eIF2α, promoted internal ribosome entry site-dependent translation of HIF1α and c-Myc, and thereby boosted the Warburg effect. In organoid-based xenografts with high BZW1 levels, both the PERK/eIF2α phosphorylation inhibitor GSK2606414 and ISRIB significantly suppressed tumor growth and prolonged animal survival.
BZW1 is a key molecule in the internal ribosome entry site-dependent translation of HIF1α/c-Myc and plays crucial roles in the glycolysis of PDAC. BZW1 might serve as a therapeutic target for patients with pancreatic cancer.
胰腺导管腺癌(PDAC)的特点是由于纤维化和血管生成不良导致严重的代谢应激。BZW1 是一种参与肿瘤发生和进展的 eIF5 模拟蛋白。本研究旨在探讨 BZW1 在 PDAC 代谢应激抵抗中的作用。
在人 PDAC 组织微阵列和 PDAC 细胞中评估了 BZW1 的表达。分析了 BZW1 对糖酵解的调节及其与糖酵解相关基因的相关性。在小鼠异种移植肿瘤和患者来源的类器官中评估了肿瘤生长、细胞增殖和细胞凋亡。
生物信息学筛选结果表明,BZW1 是 PDAC 中促进肿瘤进展的前 3 个基因之一。我们的队列分析证实,与非肿瘤组织相比,BZW1 在人 PDAC 组织中过度表达,其异常表达与肿瘤体积大、预后不良有关。BZW1 通过在缺氧-葡萄糖剥夺条件下促进糖酵解,在小鼠异种移植模型和 PDAC 衍生的类器官中促进细胞增殖并抑制细胞凋亡。机制上,BZW1 作为 PKR 样内质网(ER)激酶(PERK)的衔接物,促进 eIF2α 的磷酸化,促进 HIF1α 和 c-Myc 的内部核糖体进入位点依赖性翻译,从而促进了瓦博格效应。在高 BZW1 水平的类器官异种移植中,PERK/eIF2α 磷酸化抑制剂 GSK2606414 和 ISRIB 均显著抑制肿瘤生长并延长动物生存时间。
BZW1 是 HIF1α/c-Myc 内部核糖体进入位点依赖性翻译的关键分子,在 PDAC 的糖酵解中发挥关键作用。BZW1 可能成为胰腺癌患者的治疗靶点。